Shares of pharma company Sun Pharma saw a decline of more than 5% today. However, there was a slight improvement in the stock from the lower levels. As soon as the market opened on Monday, this stock saw a decline. Actually, a stay has been imposed on the patent related case of hair loss drug Leqselvi. By noon, Sun Pharma's stock was seen trading at ₹ 1,779.75 per share with a decline of 4.2%.

The US court has banned the launch of Leqselvi. The US company Incyte has approached the court against Sun Pharma over the patent. This drug was to be used in severe Alopecia areata. This ban on the launch of Sun Pharma's drug has been imposed till December 2026 or till the next decision. Now Sun Pharma has announced that it will appeal against this decision in the court. However, even after this, the launch time of this drug is likely to increase.

What is the possible way forward?
After this, global brokerage firm Emkay Institutional Equities believes that there is a way of settlement between Incyte and Sun Pharma on the basis of royalty. The possibility of such an agreement has increased. There was a lot of discussion about Leqselvi drug in Sun Pharma's recent earnings call. The sales potential of this drug is around $200 million in the next 3-4 years. This can be a big opportunity for Sun Pharma in terms of income. Patent dispute just a week after approval A patent dispute arose on this drug just a week after getting approval from the US FDA. Earlier, this drug was to be launched in August itself. It is believed that in the worst case scenario, by the time this decision comes, the patent of Leqselvi will expire and thus the company will be delayed in launching the drug. The royalty related to Leqselvi will depend on the settlement, but uncertainty remains about this before the court's decision. How much earning potential from the drug Nomura has estimated the launch of Leqselvi in ​​the financial year 2025. It has also said that the company is expected to earn $10 million in the financial year 2025, $80 million in the financial year 2026 and $150 million in the financial year 2027 from this drug. Nomura believes that it is likely to contribute 0.4%, 3.1% and 5.2% respectively to the company's income. However, this brokerage firm also said that if the court's decision does not change or there is no settlement, then the launch of the drug may be postponed till December 2026. In the short term, its effect can be seen on the company's earnings and investor sentiment. Let us tell you that in the July-September quarter, Sun Pharma's profit increased by 28% year-on-year to ₹ 3040 crore, which is better than analyst estimates. During this period, the company's income also increased by 9% to ₹ 13291 crore.